Healthcare / BiotechnologyHKSE
$1.83
-0.12 (-6.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-290.1M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
11.4%
↑Gross Margin
78.2%
↑Debt/Equity
-0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-5559.5%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.5M · net income $-205.1M · FCF $-194.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.5M | $3.5M | $38.4M | $39.3M | — |
| Net Income | $-205.1M | $-205.1M | $-903.4M | $-138.5M | $-2.45B |
| EBITDA | $-177.5M | $-177.5M | $-857.3M | $-45.1M | $-2.39B |
| EPS | -0.16 | -0.16 | -0.72 | -0.11 | -2.22 |
| Gross Margin | 78.2% | 78.2% | 56.2% | 61.8% | — |
| Operating Margin | -6193.0% | -6193.0% | -629.7% | -2221.6% | — |
| Net Margin | -5851.4% | -5851.4% | -2351.5% | -352.9% | — |
| Balance Sheet | |||||
| Debt/Equity | -0.01 | -0.01 | -0.05 | -0.46 | -0.53 |
| Current Ratio | 0.19 | 0.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-194.9M | $-194.9M | $-290.1M | $-737.1M | $-1.80B |
| Returns | |||||
| ROE | 11.4% | 11.4% | 55.2% | 18.9% | 367.0% |
| Growth & Yield | |||||
| Revenue Growth | -90.9% | -90.9% | -2.1% | — | — |
| EPS Growth | 77.8% | 77.8% | -554.5% | 95.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+577.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.72 → -0.16
Residual
+577.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.